What is the most likely diagnosis and recommended next steps for a 56‑year‑old female with hypertension (atenolol, losartan), diabetes (vildagliptin/metformin), allergy to phenylephrine‑containing products, who presents with a 6‑day history of dry cough worsened at night by oily/fried foods, followed by watery nasal discharge with congestion, then a productive cough with yellow sticky sputum, without fever, dyspnea, or pleuritic chest pain, and associated itching and epiphora with congested non‑erythematous turbinates?

Most Likely Diagnosis: Upper Airway Cough Syndrome (UACS) Secondary to Post-Viral Rhinitis with Possible Allergic Component

This patient has Upper Airway Cough Syndrome (UACS) triggered by a viral upper respiratory infection, with the prominent ocular symptoms (itching and epiphora) suggesting a concurrent allergic rhinitis component. 1

Clinical Reasoning

Why UACS is the Primary Diagnosis

• The 6-day progression from dry cough → watery rhinorrhea with congestion → productive cough with yellow sputum is the classic temporal pattern of post-viral UACS. 2, 1
• Nocturnal cough worsening when lying down is pathognomonic for UACS, explained by gravity-driven drainage of secretions into the hypopharynx that directly irritates cough receptors. 1
• Aggravation by oily/fried foods suggests either reflux-mediated irritation or increased upper-airway secretion production augmenting post-nasal drip. 1
• Congested turbinates on exam support the diagnosis, though physical findings alone are nonspecific—approximately 20% of UACS cases are "silent" with normal pharyngeal exams yet still respond to treatment. 2, 1

Why the Allergic Component Matters

• The "itching triad" of nasal, ocular, and palatal itching is pathognomonic for allergic rhinitis and reliably distinguishes it from non-allergic causes. 3
• Epiphora (excessive tearing) combined with ocular itching strongly suggests allergic conjunctivitis coexisting with the viral trigger. 3
• The absence of fever, myalgia, or systemic symptoms at presentation argues against active viral infection and supports a post-viral inflammatory state with allergic overlay. 3

---

Immediate Next Steps: Treatment Algorithm

Step 1: Initiate Combination Therapy (Start Today)

You cannot use standard first-line UACS therapy due to critical contraindications:

• First-generation antihistamine/decongestant combinations (the guideline-recommended first-line treatment) are contraindicated because:
  • Pseudoephedrine can worsen hypertension and cause tachycardia, which is particularly concerning in a patient on atenolol + losartan. 1, 4
  • The patient has documented allergy to phenylephrine-containing products, eliminating all oral decongestants. 1

Therefore, prescribe this modified regimen:

1. Intranasal corticosteroid: Fluticasone propionate 100–200 mcg (1–2 sprays per nostril) once daily for at least 1 month. 1, 3

   • This is the most effective monotherapy for both allergic and non-allergic rhinitis-related UACS. 1
   • Effective for post-viral inflammation and allergic rhinitis simultaneously. 5, 3

2. Ipratropium bromide nasal spray 0.03%: 2 sprays per nostril 4 times daily. 1

   • Provides anticholinergic drying effects without systemic cardiovascular side effects. 1
   • Safe alternative to oral decongestants in patients with hypertension. 1

3. High-volume nasal saline irrigation: 150 mL per nostril twice daily. 1, 5

   • Mechanically removes inflammatory mediators, mucus, and allergens. 1, 5
   • More effective than saline spray because irrigation better expels secretions. 1

4. Consider adding a first-generation antihistamine WITHOUT decongestant (e.g., diphenhydramine 25–50 mg at bedtime) to minimize sedation. 1

   • Start once-daily dosing at bedtime for a few days before increasing to twice daily if needed. 1
   • Monitor for dry mouth, urinary retention (less likely in a 56-year-old female), and transient dizziness. 1

Step 2: Symptomatic Relief

• Dextromethorphan 15–30 mg every 6–8 hours as needed for cough suppression. 1
• Ibuprofen or acetaminophen for any residual throat discomfort or headache. 5

Step 3: Monitor Blood Pressure

• Recheck blood pressure within 1 week, as her antihypertensive regimen (atenolol + losartan) may need adjustment if nasal congestion worsens control. 1, 4
• Losartan itself can cause nasal congestion (2% incidence) and upper respiratory symptoms (8% incidence), which may be contributing to her presentation. 4

---

Follow-Up Timeline

At 1–2 Weeks:

• Reassess cough severity and nasal symptoms. 1
• Most patients see improvement within days to 2 weeks of initiating UACS therapy. 1
• If no improvement after 2 weeks of adequate upper-airway treatment, proceed to Step 4. 2, 1

At 4–6 Weeks:

• Routinely follow up to assess cough severity with validated tools and verify treatment adherence. 2, 1
• Continue intranasal corticosteroid for a full month trial to assess response in allergic rhinitis. 1, 3

---

If Symptoms Persist After 2 Weeks: Sequential Evaluation

If cough persists despite adequate upper-airway treatment for 2 weeks, systematically evaluate for the other two most common causes of chronic cough: 2, 1

Step 4A: Evaluate for Asthma/Cough-Variant Asthma

• Perform spirometry; if normal, consider bronchoprovocation testing or an empiric trial of inhaled corticosteroids (e.g., fluticasone/salmeterol 250/50 mcg twice daily for 2–4 weeks). 2, 1

Step 4B: Evaluate for Gastroesophageal Reflux Disease (GERD)

• The nocturnal cough and aggravation by oily/fried foods are red flags for GERD mimicking or coexisting with UACS. 2, 1
• Initiate empiric PPI therapy: Omeprazole 20–40 mg twice daily before meals for at least 8 weeks plus dietary modifications (avoid late meals, elevate head of bed, avoid trigger foods). 2, 1
• Improvement in cough from GERD treatment may take up to 3 months. 1

Step 4C: Consider Sinus Imaging

• Obtain sinus CT only if:
  • Persistent nasal symptoms despite 2 weeks of topical therapy. 1
  • Purulent nasal discharge with facial pain/pressure. 1
  • Suspicion of bacterial sinusitis (symptoms >10 days without improvement or "double sickening"). 1, 5
• Yellow sputum alone does NOT indicate bacterial infection—it reflects neutrophil influx from viral inflammation. 1, 5

---

Critical Pitfalls to Avoid

1. Do NOT prescribe antibiotics at this visit. 1, 5

   • Yellow/sticky sputum is typical of viral infections and does not distinguish bacterial from viral etiology. 1
   • Antibiotics should not be prescribed during the first week of symptoms, even with purulent discharge. 1, 5
   • Consider antibiotics only if symptoms persist >10 days without improvement or if "double sickening" occurs (initial improvement followed by worsening after 5–7 days). 1, 5

2. Do NOT use topical nasal decongestants (oxymetazoline, xylometazoline) for more than 3–5 consecutive days due to risk of rhinitis medicamentosa (rebound congestion). 1

3. Do NOT use second-generation antihistamines (loratadine, cetirizine, fexofenadine) as monotherapy for UACS—they are ineffective because they lack anticholinergic activity. 1

4. Do NOT overlook "silent" UACS—the absence of visible post-nasal drainage or cobblestoning does not rule out the diagnosis. 1

5. Do NOT discontinue partially effective treatments prematurely—UACS, asthma, and GERD together account for ~90% of chronic cough cases and often coexist. 2, 1

6. Monitor for worsening hypertension after initiating any therapy, as decongestants (if inadvertently prescribed) can elevate blood pressure. 1, 4

---

When to Refer

• If cough persists beyond 8 weeks despite systematic treatment of UACS, asthma, and GERD, refer to a specialized cough clinic or pulmonology for bronchoscopy to investigate less common etiologies. 2, 1

• Consider allergy testing (skin prick or serum specific IgE) if:

  • No clinical response after 2–4 weeks of empiric therapy. 3
  • Persistent diagnostic uncertainty. 3
  • Need to identify exact allergens for avoidance or immunotherapy. 3

---

Special Considerations for This Patient's Comorbidities

Diabetes (Vildagliptin/Metformin):

• DPP-4 inhibitors (vildagliptin) are NOT associated with cough, unlike ACE inhibitors. 2
• Metformin does not affect blood pressure or respiratory symptoms. 6

Hypertension (Atenolol + Losartan):

• Losartan can cause nasal congestion (2%) and upper respiratory infection symptoms (8%), which may be contributing to her presentation. 4
• Atenolol does NOT cause cough (unlike ACE inhibitors), and the LIFE study confirmed that losartan has a similar cough incidence to placebo in patients with prior ACE-inhibitor cough. 4, 7
• Do NOT discontinue her antihypertensives based on this presentation—her cough is far more consistent with UACS than drug-induced cough. 2, 4

Allergy History:

• Her documented allergy to phenylephrine + chlorpheniramine + paracetamol and dextromethorphan + phenylpropanolamine + paracetamol (Tuseran Forte) eliminates all oral decongestants and most combination cold products. 1
• This necessitates the modified regimen above (intranasal corticosteroid + ipratropium + saline irrigation). 1